Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 22,009 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: ICI-refractory, Non-Small Cell Lung Cancer
Interventions: SAR445877; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Insomnia, Nightmares, Nightmares Associated With Trauma and Stress, PTSD - Post Traumatic Stress Disorder
Interventions: Cognitive Behavioral Therapy for Insomnia, Cognitive Behavioral Therapy for Insomnia and Nightmares, Sleep Education, Sleep Education enhanced with Nightmare Education; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Advanced Stage Solid Tumors
Interventions: Amivantamab, JNJ-95437446; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Sarasota, Florida • New York, New York • Nashville, Tennessee + 1 more

Conditions: Prostatic Neoplasms
Interventions: JNJ-78278343, JNJ-87189401, JNJ-95298177; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Sarasota, Florida • New York, New York • Cleveland, Ohio + 1 more

Conditions: Heart Failure - NYHA II - IV
Interventions: CRT-D with INGEVITY+ pace/sense lead, CRT-D with a Quadripolar LV lead; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 43
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more

Conditions: Gastroesophageal Adenocarcinoma
Interventions: 5-Fluorouracil (5-FU), Calcium folinate, Capecitabine, FLOT Chemotherapy, Rilvegostomig, Sonesitatug Vedotin, Trastuzumab Deruxtecan (T-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more

Conditions: Multiple Sclerosis (MS) Primary Progressive
Interventions: Orelabrutinib, Placebo; Drug
Lead sponsor: Zenas BioPharma (USA), LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 19
States / cities: Pheonix, Arizona • Scottsdale, Arizona • West Hollywood, California + 15 more

Conditions: Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma, Stage II Endometrial Cancer, Stage III Endometrial Cancer, Stage IV Endometrial Cancer
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor; Procedure · Biological · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 182
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 146 more

Conditions: Breast Neoplasms
Interventions: Capecitabine, Nab-paclitaxel, Paclitaxel, Patritumab deruxtecan, Pegylated liposomal doxorubicin, Rescue Medication, Trastuzumab deruxtecan; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 35
States / cities: Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 28 more

Conditions: Advanced Small Intestine Cancer, Appendiceal Cancers
Interventions: Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Degenerative Spine Disease
Interventions: Demineralized Bone Matrix, FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute; Device
Lead sponsor: DePuy Synthes Products, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Sacramento, California • Chicago, Illinois • Lexington, Kentucky + 2 more

Conditions: Cystic Fibrosis (CF)
Interventions: Not listed
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Months to 11 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Hollywood, Florida + 10 more

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Asciminib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Survey Administration; Drug · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: NALIRIFOX, Paclitaxel; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Alzheimer's Disease
Interventions: Placebo, Xanomeline Enteric Capsule, Xanomeline/Trospium Chloride Capsule; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 42
States / cities: Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more

Conditions: Chemotherapy-induced Peripheral Neuropathy (CIPN), Healthy
Interventions: No intervention (observational study); Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atopic Dermatitis
Interventions: APG777; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more

Conditions: PIK3CA-related Overgrowth Spectrum (PROS)
Interventions: Alpelisib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 10
States / cities: Sacramento, California • St Louis, Missouri • Chapel Hill, North Carolina + 6 more

Conditions: Cutaneous Sarcoidosis
Interventions: Oral Brepocitinib, Oral Placebo; Drug
Lead sponsor: Priovant Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Adolescent Development, Anxiety, Substance Use
Interventions: Trier Social Stress Test; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 14 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Orthopaedic Fractures, Socioeconomic Factors
Interventions: Social Work support; Other
Lead sponsor: Sheila Sprague; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Dry Powder Inhaler, LTI-03, Placebo; Device · Drug
Lead sponsor: Rein Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
Interventions: Obinutuzumab, Pirtobrutinib, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

Restorative Early Sleep Treatment After the Emergency Department

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

FIBERGRAFT Aeridyan Posterolateral Fusion Study

TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

Adverse Adolescent Pathways to Substance Use

Trial of Social Work Services in Fracture Clinic Setting

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).